WO2001091711A1 - Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases - Google Patents
Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases Download PDFInfo
- Publication number
- WO2001091711A1 WO2001091711A1 PCT/EP2001/006268 EP0106268W WO0191711A1 WO 2001091711 A1 WO2001091711 A1 WO 2001091711A1 EP 0106268 W EP0106268 W EP 0106268W WO 0191711 A1 WO0191711 A1 WO 0191711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- depot
- internationale
- date
- autorite
- micro
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 61
- 241000186045 Actinomyces naeslundii Species 0.000 title claims abstract description 26
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 208000002064 Dental Plaque Diseases 0.000 claims abstract description 17
- 230000009036 growth inhibition Effects 0.000 claims abstract description 15
- 244000005706 microflora Species 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 208000008655 root caries Diseases 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 51
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 23
- 235000013365 dairy product Nutrition 0.000 claims description 19
- 241000186046 Actinomyces Species 0.000 claims description 8
- 108010062877 Bacteriocins Proteins 0.000 claims description 8
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 235000001252 Lactococcus lactis subsp lactis bv diacetylactis Nutrition 0.000 claims description 5
- 241000168725 Lactococcus lactis subsp. lactis bv. diacetylactis Species 0.000 claims description 5
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 3
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 claims 28
- 238000006243 chemical reaction Methods 0.000 claims 12
- 241001275800 Zanclidae Species 0.000 claims 7
- 101150093826 par1 gene Proteins 0.000 claims 4
- 241000518994 Conta Species 0.000 claims 1
- 241001331845 Equus asinus x caballus Species 0.000 claims 1
- 229920000825 Fique Polymers 0.000 claims 1
- 241000186044 Actinomyces viscosus Species 0.000 description 22
- 210000000214 mouth Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 241000194035 Lactococcus lactis Species 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 9
- 235000013618 yogurt Nutrition 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000008485 antagonism Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 6
- 239000003876 biosurfactant Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000132734 Actinomyces oris Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000194036 Lactococcus Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- 229940034610 toothpaste Drugs 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000193987 Streptococcus sobrinus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001013 cariogenic effect Effects 0.000 description 3
- 239000006781 columbia blood agar Substances 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000021195 test diet Nutrition 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000191953 Kocuria varians Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 241001533204 Veillonella dispar Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000404 calcium aluminium silicate Substances 0.000 description 1
- 235000012215 calcium aluminium silicate Nutrition 0.000 description 1
- WNCYAPRTYDMSFP-UHFFFAOYSA-N calcium aluminosilicate Chemical compound [Al+3].[Al+3].[Ca+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O WNCYAPRTYDMSFP-UHFFFAOYSA-N 0.000 description 1
- 229940078583 calcium aluminosilicate Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000001315 dental pellicle Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000015227 regulation of liquid surface tension Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960000340 thiopental sodium Drugs 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108010005406 variacin Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G4/123—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2220/00—Biochemical treatment
- A23C2220/20—Treatment with microorganisms
- A23C2220/206—Slime forming bacteria; Exopolysaccharide or thickener producing bacteria, ropy cultures, so-called filant strains
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Definitions
- the present invention relates to the incorporation in the oral microflora of exogenous lactic bacteria which are able to modulate the colonization of A. naeslundii and to reduce the severity of A. naeslundii-r&ldited diseases.
- the mouth (oral cavity) contains a resident and a non-resident microflora.
- the first includes microorganisms that are able to establish a more or less permanent residence on the oral surfaces. These bacteria are mainly localised on the tongue, the buccal mucosa and the teeth while the gingiva, lips, cheeks, palate and floor of the mouth only support a very sparse microflora.
- the dental plaque is a film that forms on the surface of teeth consisting of bacterial cells in a matrix of extracellular polysaccharides and salivary products. Immediately after eruption, the teeth are covered with an amorphous layer of saliva, the acquired enamel pellicle (AEP) that is about 1.3 ⁇ m thick and cannot be removed by normal tooth brushing.
- AEP acquired enamel pellicle
- the deposition of bacteria on teeth follows immediately the formation of the AEP and plaque becomes evident in 8- 12 hours as a multi-layered structure.
- the first layer consists of bacteria (earliest colonisers) that attach to teeth mainly via specific adhesin-receptor recognition; it forms a substratum for the second colonisers that adhere one to the other via analogous specific binding or via simple juxtaposition.
- the natural resident microflora includes microorganisms selected from Streptococcus, Veillonella, Bacteroides and Haemophilus.
- Streptococci and Actinomyces predominate but a variety of Gram positive and negative cocci and rods can be found.
- Actinomyces naeslundii genospecies 1 (formerly A. naeslundi ⁇ ) and 2 (formerly A. viscosus) are common members of human dental plaque. They are among the strongest plaque forming oral strains, because of their capacity to firmly adhere to the teeth and to coaggregate with many other bacterial species, thus fostering their establishment in the mouth.
- the transient microflora comprises exogenous bacteria that can be occasionally present in the mouth, but that do not establish a permanent residence
- All the food bacteria, and in particular lactic acid bacteria, can be part of this transient microflora.
- lactic bacteria strains that are not part of the resident microflora of the mouth, that are low acidifying and that are capable of adhering directly to the pellicle of the teeth.
- These bacteria are particularly used for treating or preventing dental caries and periodontal infection that are caused by cariogenic microorganism such as Streptococcus mutans and Streptococcus sobrinus.
- Exogenous bacteria can also produce factors that inhibit the growth of the resident microflora in the mouth.
- EP759469 Societe des Produits Nestle
- bacteriocins produced by Micrococcus varians for inhibiting the development of the oral pathogens S. sobrinus, S. sanguis, S. mutans and A. viscosus.
- the application of bacteriocins is also one of the investigated strategies which have been set up to reduce tooth caries. These molecules have attracted interest as prospective anticaries agents and as factors important in modulating colonisation of the oral cavity.
- the present invention aims to provide the use of lactic bacteria that are exogenous to the oral microflora, which have been selected for their ability to adhere to the tooh surface and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries or other disease related to Actinomyces naeslundii in mammals.
- the lactic bacteria may be selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and particularly from the group consisting of the strains CNCM 1-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987.
- Another object is to provide a composition for maintaining the health of the mouth by reducing the colonization of Actinomyces naeslundi, said composition comprises an exogenous lactic bacteria that has been selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
- Such a composition may contain at least 10 4 -10 9 cfu /g of lactic bacteria.
- the invention also provides a method for the prevention or the treatment of Actinomyces naeslundi related infections, particularly dental plaque extent and root caries in a mammal, comprising the step of feeding a mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor, said composition reduces the colonization of Actinomyces naeslundi.
- the mouth defines the oral cavity of humans or animals such as pets, composed by the oral mucosa (gums, lips, cheeks, palate and floor of the mouth), the tongue and the teeth (including artificial structures).
- inhibitor growth factor defines any extracellular substance produced by the adherent exogenous lactic bacteria that enables it to inhibit the growth of A.naeslundi.
- the use of an exogenous lactic bacteria that has been selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries or other disease related to Actinomyces naeslundi, is concerned.
- the lactic bacteria may be selected from the group consisting of
- Streptococcus thermophilus Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and particularly from the group consisting of the strains Sreptococcus thermophilus (NCC 1529) (CNCM 1-1984),
- the lactic bacteria is preferably from dairy origin (i.e. originating from milk or cheese, for example).
- the lactic bacteria according to the invention is "low acidifying", which means that it is less acidifying than pathogenic strains. Accordingly, it can contribute to a pH in the oral cavity of about 5.5-7.
- strains have been selected among latic bacteria strains for their capacity of adherence to the pellicle of the teeth, their optimal growth temperature is about 37°C, which is the temperature in the oral cavity. They are also capable of producing a growth inhibition factor, which combined to their adhesion properties allow them to significantly decrease the colonization extent of A. naeslundii genospecies 1 and 2.
- At least one lactic bacteria strain in combination with a bacteriocin, for example.
- the lactic bacteria strains may be included in a food, pet food, cosmetic or pharmaceutical composition, for example. Accordingly, these compositions are preferably toothpaste, mouth rinse, gum, spray, beverage, candies, infant formula, ice cream, frozen dessert, sweet salad dressing, milk preparations, cheese, quark, yogurt, acidified milk, coffee cream or whipped cream, for example.
- the exogenous lactic bacteria may be used in an amount of at least 10 4 - 10 9 cfu /g of lactic bacteria.
- the effect of incorporating the above-mentioned bacteria in the oral microflora was tested in a rat model.
- the strains CNCM 1-1985 and CNCM- 1986 were able to modulate the oral microbial ecology, significatively reducing the number of total CFU. More specifically, the strains were able to significantly decrease the colonization extent of A. naeslundii genospecies 2, with which the rats had been infected (see examples).
- Fermentation patterns 49 simple sugars were tested with the api 50 CH bioMerieux strip test (bioMerieux SA, 69280 Marcy-l'Etoile, France) and the results are given in Table 1.
- strains Sreptococcus thermophilus (NCC 1529), Sreptococcus thermophilus (NCC 1561), Lactococcus. lactis subsp. lactis (NCC 2211), Lactococcus. lactis subsp. lactis biovar dioacetylactis (NCC 2225) were deposited under the Budapest Treaty, at the Collection Nationale de Culture de Microorganismes (CNCM 1-1984, CNCM 1-1985, CNCM 1-1986 and CNCM I- 1987 respectively), 25 rue du dondel Roux, 75724 Paris, France, on March 3 rd , 1998.
- the second main object of the present invention relates to a composition for maintaining the health of the mouth by reducing the colonization of A. naeslundii in mammals, said composition comprises an exogenous lactic bacteria, which has been selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
- compositions are particularly intended for the prophylaxis or the treatment of dental plaque and infection related to A. naeslundii disease such as root caries, for example.
- the lactic bacteria strain according to the present invention is selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and preferably from the group consisting of the strains CNCM 1-1984, CNCM I-
- Such a ; composition may contain at least 10 4 -10 9 cfu /g of lactic bacteria.
- Synergistic compositions may also be prepared, adding at least one bacteriocin, which is active against Gram-positive oral bacteria.
- the oral hygiene compositions may comprise 0.00001 to 50%, and preferably from 0.00001 to 15% of purified bacteriocin, by weight of the composition.
- the bacteriocin is preferably variacin (EP 0 759 469).
- an oil-soluble antioxidant may also be included. Suitable antioxidants include the “tocopherols", butyl-hydroxyanisole (BHA), butyl-hydrxytoluene (BHT), and ascorbyl palmitate.
- BHA butyl-hydroxyanisole
- BHT butyl-hydrxytoluene
- ascorbyl palmitate ascorbyl palmitate.
- the oil soluble antioxidant is present in amounts of from
- Suitable abrasives for use in dentifrice compositions of the present invention include calcium carbonate, calcium aluminosilicate, alumina, hydrates alumina, zinc orthophosphate, plastic particles, and silica, of which silica is the preferred abrasive.
- compositions according to the invention will have a pH which is orally acceptable and within which the activity of the said lactic bacteria is not compromised.
- the pH may be in the range 3.0-9.5, preferably in the range 3.5 to 6.5.
- These compositions may be prepared by conventional processes comprising admixing the ingredients together in the appropriate relative amounts and finally, and if necessary, adjusting the pH to desired value.
- Actinomyces naeslundii genospecies 1 (formerly A. naeslundii) and 2 (formerly A. viscosus) are among the strongest plaque forming oral strains. They are commonly isolated at root caries sites, in particular in humans over 40 years, and they are believed to be the major aetiological agent of this disease.
- the invention also provides a method for the prevention or the treatment of Actinomyces naeslundi-r&lated infections in mammals, particularly dental plaque extent and root caries, comprising the step of feeding the mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
- the amount to be administred may be of at least about 10 4 -10 9 cfu /g of lactic bacteria.
- L. lactis NCC2211 The strains S. thermophilus NCC 1561 (CNCM 1-1985) and L. lactis subsp. lactis NCC2211 (CNCM 1-1986) (hereinafter L. lactis NCC2211) were incorporated in vitro in a biofilm mimicking dental plaque in vitro.
- the two selected strains L. lactis NCC2211 and S. thermophilus NCC1561 were inoculated in an in vitro system in which a biofilm, composed by bacteria commonly found in the human mouth after 40 years, developed on saliva coated-hydroxyapatite discs.
- Fluid Universal Medium FUM
- the assays were done in triplicate and the mixtures with and without the dairy strains were tested in parallel.
- the strains listed in the Table 2 were used.
- Saliva pellicle formation cover synthetic hydroxyapatite discs of 10 mm diameter (HY-APATITE ® , Euro-Crystals, Landgraaf, The Netherlands) with 800 ⁇ l of human saliva and incubate for 4 h at room temperature under shaking (1 disc/well in a 24 holes sterile Nunclon plate).
- Bacterial consortium preparation grow S. thermophilus NCC1561, L. lactis subsp. lactis NCC2211, S. sobrinus OMZ176, S. oralis OMZ607, A. naeslundii OMZ745, V. dispar OMZ493 and F.
- nucleatum OMZ596 overnight at 37°C in anaerobiosis in FUM-glucose (S. thermophilus NCC1561 in FUM-lactose), adjust the OD 550 to 1 with FUM and pool 2 ml of each oral bacterial suspension with 2 ml of either S. thermophilus NCC1561 or L. lactis subsp. lactis NCC2211.
- the control mixture contains the five oral strains only.
- thermophilus NCC 1561 and L. lactis NCC2211 could be incorporated and grown in the plaque-like biofilm on the S-HA discs, and their total CFU/disc after 40.5 h are given in the Table 4.
- N 3. *: p-values are calculated in respect to the control (*: p ⁇ 0.05; **: p ⁇ 0.01); °: p- values are calculated in respect to the "+NCC1561" treatment (°: ⁇ 0.05; °°: p ⁇ 0.01).
- N 3. *: p-values are calculated in respect to the control (*: p ⁇ 0.05; **: p ⁇ 0.01); °: p- values are calculated in respect to the "+NCC2211" treatment (°: p ⁇ 0.05; °°: p ⁇ 0.01).
- S. thermophilus NCC1561 and L. lactis NCC2211 could be incorporated in a biofilm mimicking dental plaque and were able to modulate the oral microflora, significantly reducing the number total of cfu, and more specifically, these strains were able to significantly decrease the colonization extent of A. naeslundii genospecies 2. In addition the strains could inhibit the growth of A. naeslundii genospecies 1 and 2 in co-cultures.
- Example 2 in- vivo trials.
- the cariogenic strains were associated on days 21 and 22, while association of the dairy strains started on day 23 and lasted until day 57.
- the animals were fed the dairy strains as supplement in a yogurt base that was included in the normal diet, as explained in the section.
- the rats teeth were swabbed at the end of the study, on day 58.
- the rats On day 20 the dams were removed, and the rats started to be fed ad libitum with the modified diet 2000a containing 40% sucrose, 28% substitute for skim milk (soya protein extract SVPRO-PP 1611 39.4%, lactose 49.3%, 0.6%, L- Methionine 0.3%, L-Lysine HC1 0.1%), 24% wheat flour, 5% brewer's yeast, 2% Gevral ® Instant Protein (Whitehall-Robins SA, 6301 Switzerland) and 1% NaCl. During the association period (days 21 and 22) the drinking water was supplemented with 2% glucose and 2% sucrose to support the implantation of the associated bacteria.
- test diet consisted of 18 yogurt meals containing the test strains alternating with 18 meals of the modified diet 2000a previously described.
- Bacterial strains The strains listed in the Table 8 were used.
- mice were arranged in 3 treatments (Table 9). Each treatment consisted of 10 pups that were distributed in 1 per cage.
- the tested LAB strains were associated daily (since contained in the yogurt base meal), starting on day 23. 2 frozen vials, each containing 2xlO ⁇ viable cells of the test strain, were mixed in 200 ml of yogurt in order to have at least 10 9 CFU/ml. S. thermophilus NCC1536, a non S-HA adhering strain, was used as a negative control.
- the yogurt and diet 2000a meals were offered alternatively 18 times per day at 20-min intervals (Table 10). Therefore, each animal received in total 18 ml of yogurt and 7.2 g of powdered diet.
- the meals were dispensed in the food cups of a programmed feeder machine that automatically offered to the animals the right meal at the exact time.
- mice Five rats per treatment were swabbed on day 58.
- the swab suspensions were either plated on Petri dishes for CFU (colony forming units) counts or immobilized on glass slides for immunofluorescence for TCN (total cells number) counts.
- the percentages of A. viscosus OMZ105 on the total CFU did not decrease in parallel, therefore one can deduce that the growth antagonism effect was also displayed versus other species, i.e. Veillonellae, and consequently it is a global effect which is observed.
- strains CNCM 1-1985 and CNCM- 1986 are able to modulate the oral microbial ecology, significatively decreasing the colonization extent of A. naeslundii genospecies 2, with which the rats had been infected.
- Example 3 Production and initial analysis of surfactant substances from S. thermophilus NCC1561 and S. thermophilus NCC1536.
- thermophilus NCC1561 and S. thermophilus NCC1536 were grown overnight in 1 1 of Belliker at 42 °C.
- the procedure described in Busscher et al. (1997) Appl. Environ. Microbiol. 63, 3810-3817, (Busscher et al., 1997) was used.
- the crude biosurfactant suspension was first analyzed by SDS-PAGE and then submitted to surface tension measurements.
- S. thermophilus NCC1561 and S. thermophilus NCC1536 cells are able to release substances with a surfactant activity. It is therefore possible that the biosurfactant produced by S. thermophilus NCC 1561 makes the bacterium itself and the other oral strains established close to it detach from the tooth surface. By contrast, this action would not be displayed by S. thermophilus NCC 1536, since this strain does not adhere to the teeth.
- Toothpaste is prepared by adding 10 5 cfu/ml of at least one of the lactic bacteria strain CNCM 1-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987 in a lyophilised form, to the following mixture containing: 1.65% Cetyl pyridinium chloride, 33.0% Sorbitol (70% soln), 25.0% Glycerin, 2.0% Sodium carboxymethyl cellulose, 0.25% Sodium fluoride, 26.3% Silica (RP 93), 8.1% Thickening Silica (Sident 22), 0.5% Sodium saccharine, 3.2% Poloxamer (Pluronic F108).
- This toothpaste is intended for the prophylaxis or the treatment of root caries, dental plaque and other infections induced by A.naeslundii species.
- 5 1 MRS culture medium are sterilised for 15 min at 121°C and then inoculated with 5% by volume of an active culture of at least one of the S. thermophilus strain CNCM 1-1984, CNCM 1-1985 containing approximately 10 cfu/ml. After incubation for 8 h at 41°C, a starter containing 4.5.10 cfu/ml is obtained.
- the yoghurt obtained has a good firm and smooth texture and is intended for the health of the mouth.
- a chewing gum for preventing or treating root caries, dental plaque or other A.naeslundii- ⁇ ela.ted deseases can be prepared adding an active culture of at least one of the S. thermophilus strain CNCM 1-1984, CNCM 1-1985 so that it contains approximately 10 4 to 10 9 cfu/g, to the following typical ingredients: 67.5 % Xylitol, 20 % Gum base, 5 % Calcium carbonate, 3 % Glycerin, 2 % Pluronic F127, 1 % Cellulose gum, 0.5 % Balast compounds and 1 % Flavor.
- a pet food for mouth health is obtained by preparing a feed mixture made up of corn, corn gluten chicken and fish meal, salts, vitamins and minerals.
- the feed mixture is fed into a preconditioner and moistened.
- the moistened feed leaving the preconditioner is then fed into an extruder-cooker and gelatinised.
- the gelatinised matrix leaving the extruder is forced through a die and extruded.
- the extrudate is cut into pieces suitable for feeding to dogs, dried at about 110°C for about 20 minutes and cooled to form pellets which have a water activity of about 0.6.
- the pellets are sprayed with 3 coating mixtures.
- Each coating mixture contains active culture of at least one of the S.
- the pellets contain approximately 10 4 to 10 9 cfu/g of said strains.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The use of a lactic bacteria strain that is exogenous to the oral microflora, which has been selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.
Description
Use of exogenous lactic bacteria strain against Actinomyces naeslundii- related diseases
The present invention relates to the incorporation in the oral microflora of exogenous lactic bacteria which are able to modulate the colonization of A. naeslundii and to reduce the severity of A. naeslundii-r&ldited diseases.
Background of the invention
The mouth (oral cavity) contains a resident and a non-resident microflora.
The first includes microorganisms that are able to establish a more or less permanent residence on the oral surfaces. These bacteria are mainly localised on the tongue, the buccal mucosa and the teeth while the gingiva, lips, cheeks, palate and floor of the mouth only support a very sparse microflora.
The dental plaque is a film that forms on the surface of teeth consisting of bacterial cells in a matrix of extracellular polysaccharides and salivary products. Immediately after eruption, the teeth are covered with an amorphous layer of saliva, the acquired enamel pellicle (AEP) that is about 1.3 μm thick and cannot be removed by normal tooth brushing. The deposition of bacteria on teeth follows immediately the formation of the AEP and plaque becomes evident in 8- 12 hours as a multi-layered structure. The first layer consists of bacteria (earliest colonisers) that attach to teeth mainly via specific adhesin-receptor recognition; it forms a substratum for the second colonisers that adhere one to the other via analogous specific binding or via simple juxtaposition.
On the tongue and the buccal mucosa, the natural resident microflora includes microorganisms selected from Streptococcus, Veillonella, Bacteroides and Haemophilus. On the teeth, Streptococci and Actinomyces predominate but a variety of Gram positive and negative cocci and rods can be found.
Many of these microorganisms are innocuous commensal, but a lot of them have been recognised as the etiologic agent of quite a few diseases (Hill, M. J. and Marsh, P. D. eds. Human Microbial Ecology, 1990, CRC Press, Boca Raton Florida, USA).
In particular, Actinomyces naeslundii genospecies 1 (formerly A. naeslundiϊ) and 2 (formerly A. viscosus) are common members of human dental plaque. They are among the strongest plaque forming oral strains, because of their capacity to firmly adhere to the teeth and to coaggregate with many other bacterial species, thus fostering their establishment in the mouth. Moreover, in the elderly, they are commonly isolated at root caries sites, and they are believed to be the major aetiological agent of this disease (Bowden, G.H., et al. 1999, The diversity and distribution of the predominant ribotypes of Actinomyces naeslundii genospecies 1 and 2 in samples from enamel and from healthy and carious root surfaces of teeth. J.Dent.Res. 78, 1800-1809).
The transient microflora comprises exogenous bacteria that can be occasionally present in the mouth, but that do not establish a permanent residence
(even if repeated oral administrations of these bacteria are carried out). All the food bacteria, and in particular lactic acid bacteria, can be part of this transient microflora.
Some of these exogenous lactic bacteria have been shown to be capable of adhering to the pellicle of teeth. For example, WO 00/09080 (Societe des Produits Nestle) discloses lactic bacteria strains, that are not part of the resident microflora of the mouth, that are low acidifying and that are capable of adhering directly to the pellicle of the teeth. These bacteria are particularly used for treating or preventing dental caries and periodontal infection that are caused by cariogenic microorganism such as Streptococcus mutans and Streptococcus sobrinus.
Exogenous bacteria can also produce factors that inhibit the growth of the resident microflora in the mouth. For example, EP759469 (Societe des Produits Nestle) described the use of a bacteriocin produced by Micrococcus varians for inhibiting the development of the oral pathogens S. sobrinus, S. sanguis, S. mutans and A. viscosus. The application of bacteriocins is also one of the investigated strategies which have been set up to reduce tooth caries. These molecules have attracted interest as prospective anticaries agents and as factors important in modulating colonisation of the oral cavity.
It is to note that the prior art does not provide any information concerning strains that can establish in the oral cavity by directly adhering to the pellicle of
the teeth and also produce factors such as growth inhibition factors, which can modulate the colonization of A. naeslundii so as to reduce the severity of A. naeslundii-relatQά diseases.
Summary of the invention
Consequently the present invention aims to provide the use of lactic bacteria that are exogenous to the oral microflora, which have been selected for their ability to adhere to the tooh surface and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries or other disease related to Actinomyces naeslundii in mammals.
The lactic bacteria may be selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and particularly from the group consisting of the strains CNCM 1-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987.
Thus, by colonising the surface of teeth and producing growth inhibition factors, such lactic bacteria can exert an significant reduction of the extent of Actinomyces naeslundii, thus reducing dental plaque, .root caries and other Actinomyces naeslundii related infections.
Another object is to provide a composition for maintaining the health of the mouth by reducing the colonization of Actinomyces naeslundi, said composition comprises an exogenous lactic bacteria that has been selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
Such a composition may contain at least 104-109 cfu /g of lactic bacteria.
The invention also provides a method for the prevention or the treatment of Actinomyces naeslundi related infections, particularly dental plaque extent and root caries in a mammal, comprising the step of feeding a mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor, said composition reduces the colonization of Actinomyces naeslundi.
Detailed description of the invention
Within the following description, the mouth defines the oral cavity of humans or animals such as pets, composed by the oral mucosa (gums, lips, cheeks, palate and floor of the mouth), the tongue and the teeth (including artificial structures).
The terms "inhibition growth factor" defines any extracellular substance produced by the adherent exogenous lactic bacteria that enables it to inhibit the growth of A.naeslundi.
With respect to the first object of the present invention, the use of an exogenous lactic bacteria that has been selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries or other disease related to Actinomyces naeslundi, is concerned.
The lactic bacteria may be selected from the group consisting of
Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and particularly from the group consisting of the strains Sreptococcus thermophilus (NCC 1529) (CNCM 1-1984),
Sreptococcus thermophilus (NCC 1561) (CNCM 1-1985), Lactococcus. lactis subsp. lactis (NCC 2211) (CNCM 1-1986), Lactococcus. lactis subsp. lactis biovar dioacetylactis (NCC 2225) (CNCM 1-1987).
The lactic bacteria is preferably from dairy origin (i.e. originating from milk or cheese, for example).
The lactic bacteria according to the invention is "low acidifying", which means that it is less acidifying than pathogenic strains. Accordingly, it can contribute to a pH in the oral cavity of about 5.5-7.
These strains have been selected among latic bacteria strains for their capacity of adherence to the pellicle of the teeth, their optimal growth temperature is about 37°C, which is the temperature in the oral cavity. They are also capable of producing a growth inhibition factor, which combined to their
adhesion properties allow them to significantly decrease the colonization extent of A. naeslundii genospecies 1 and 2.
Moreover they are capable of fermenting glucose and sucrose and do not synthesise glucans, which are factors of pathogenicity of the cariogenic strains.
It is also possible to use at least one lactic bacteria strain in combination with a bacteriocin, for example.
The lactic bacteria strains may be included in a food, pet food, cosmetic or pharmaceutical composition, for example. Accordingly, these compositions are preferably toothpaste, mouth rinse, gum, spray, beverage, candies, infant formula, ice cream, frozen dessert, sweet salad dressing, milk preparations, cheese, quark, yogurt, acidified milk, coffee cream or whipped cream, for example.
The exogenous lactic bacteria may be used in an amount of at least 104- 109 cfu /g of lactic bacteria.
The effect of incorporating the above-mentioned bacteria in the oral microflora was tested in a rat model. The strains CNCM 1-1985 and CNCM- 1986 were able to modulate the oral microbial ecology, significatively reducing the number of total CFU. More specifically, the strains were able to significantly decrease the colonization extent of A. naeslundii genospecies 2, with which the rats had been infected (see examples).
BIOCHEMICAL CHARACTERIZATION OF THE SELECTED STRAINS
Fermentation patterns: 49 simple sugars were tested with the api 50 CH bioMerieux strip test (bioMerieux SA, 69280 Marcy-l'Etoile, France) and the results are given in Table 1.
Table 1. Sugar fermentation of L. lactis CNCM I- 1987 (A), L. lactis CNCM I- 1986 (B), S. thermophilus CNCM 1-1984 (C), S. thermophilus CNCM 1-1985 (D).
The strains Sreptococcus thermophilus (NCC 1529), Sreptococcus thermophilus (NCC 1561), Lactococcus. lactis subsp. lactis (NCC 2211), Lactococcus. lactis subsp. lactis biovar dioacetylactis (NCC 2225) were deposited under the Budapest Treaty, at the Collection Nationale de Culture de Microorganismes (CNCM 1-1984, CNCM 1-1985, CNCM 1-1986 and CNCM I- 1987 respectively), 25 rue du docteur Roux, 75724 Paris, France, on March 3rd, 1998.
The second main object of the present invention relates to a composition for maintaining the health of the mouth by reducing the colonization of A.
naeslundii in mammals, said composition comprises an exogenous lactic bacteria, which has been selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
These compositions are particularly intended for the prophylaxis or the treatment of dental plaque and infection related to A. naeslundii disease such as root caries, for example.
The lactic bacteria strain according to the present invention is selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and preferably from the group consisting of the strains CNCM 1-1984, CNCM I-
1985, CNCM 1-1986 and CNCM 1-1987.
Such a;composition may contain at least 104-109 cfu /g of lactic bacteria.
Synergistic compositions may also be prepared, adding at least one bacteriocin, which is active against Gram-positive oral bacteria. In that case, the oral hygiene compositions may comprise 0.00001 to 50%, and preferably from 0.00001 to 15% of purified bacteriocin, by weight of the composition. The bacteriocin is preferably variacin (EP 0 759 469).
In order to protect the composition from degradation, an oil-soluble antioxidant may also be included. Suitable antioxidants include the "tocopherols", butyl-hydroxyanisole (BHA), butyl-hydrxytoluene (BHT), and ascorbyl palmitate. The oil soluble antioxidant is present in amounts of from
0.005% to 0.5%, preferably 0.005% to 0.01% by weight of the composition.
Suitable abrasives for use in dentifrice compositions of the present invention include calcium carbonate, calcium aluminosilicate, alumina, hydrates alumina, zinc orthophosphate, plastic particles, and silica, of which silica is the preferred abrasive.
Compositions according to the invention will have a pH which is orally acceptable and within which the activity of the said lactic bacteria is not compromised. The pH may be in the range 3.0-9.5, preferably in the range 3.5 to 6.5.
These compositions may be prepared by conventional processes comprising admixing the ingredients together in the appropriate relative amounts and finally, and if necessary, adjusting the pH to desired value.
Actinomyces naeslundii genospecies 1 (formerly A. naeslundii) and 2 (formerly A. viscosus) are among the strongest plaque forming oral strains. They are commonly isolated at root caries sites, in particular in humans over 40 years, and they are believed to be the major aetiological agent of this disease.
Thus, the invention also provides a method for the prevention or the treatment of Actinomyces naeslundi-r&lated infections in mammals, particularly dental plaque extent and root caries, comprising the step of feeding the mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
The amount to be administred may be of at least about 104-109 cfu /g of lactic bacteria.
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the claims. Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties to the extent necessary for understanding the present invention.
Example 1: in-vitro trials
The strains S. thermophilus NCC 1561 (CNCM 1-1985) and L. lactis subsp. lactis NCC2211 (CNCM 1-1986) (hereinafter L. lactis NCC2211) were incorporated in vitro in a biofilm mimicking dental plaque in vitro.
The oral strain A. naeslundii genospecies 1 (formerly A. naeslundii) OMZ745 and A. naeslundii genospecies 2 (formerly A. viscosus) OMZ105 were obtained from the Institute fur Orale Mikrobiologie und Allgemeine
Immunologie, University of Zurich and they were cultured in FUM medium in anaerobiosis (GasPackSystem, BBL) at 37°C.
All the strains were stored in glycerol at -20°C and precultured for 14 hours prior to use at their specific optimal temperature;
The two selected strains L. lactis NCC2211 and S. thermophilus NCC1561 were inoculated in an in vitro system in which a biofilm, composed by bacteria commonly found in the human mouth after 40 years, developed on saliva coated-hydroxyapatite discs. Fluid Universal Medium (FUM), the growth medium used, was especially formulated to buffer the acidity produced by the test strains and to have therefore a continued growth (plaque development), like it is in the mouth (Gmur and Guggenheim, 1983). The assays were done in triplicate and the mixtures with and without the dairy strains were tested in parallel. The strains listed in the Table 2 were used.
Table 2. Bacterial strains used and culture conditions applied in the in vitro dental plaque experiments.
Procedure
- Saliva pellicle formation: cover synthetic hydroxyapatite discs of 10 mm diameter (HY-APATITE®, Euro-Crystals, Landgraaf, The Netherlands) with 800 μl of human saliva and incubate for 4 h at room temperature under shaking (1 disc/well in a 24 holes sterile Nunclon plate).
- Bacterial consortium preparation: grow S. thermophilus NCC1561, L. lactis subsp. lactis NCC2211, S. sobrinus OMZ176, S. oralis OMZ607, A. naeslundii OMZ745, V. dispar OMZ493 and F. nucleatum OMZ596 overnight at 37°C in anaerobiosis in FUM-glucose (S. thermophilus NCC1561 in FUM-lactose), adjust the OD550 to 1 with FUM and pool 2 ml of each oral bacterial suspension with 2 ml of either S. thermophilus NCC1561 or L. lactis subsp. lactis NCC2211. The control mixture contains the five oral strains only.
- Biofilm formation and recovery; the procedure is as described in Guggenheim et al., 1998, Validation of a new biofilm model. J.Dent.Res. 77, (Spec Iss A): 110
(Abstract #38).
- Cultural analysis of the biofilm: spiral plate the suspension on Columbia Blood Agar (5% sheep blood, Becton Dickinson, Meylan Cedex, France) for the total count and for the differentiation of A. naeslundii. Incubate the plates at 37°C in anaerobiosis for 48 h.
Growth antagonism between the oral and the dairy strains under study Strains and culture conditions used are listed in the Table 3.
Table 3 Bacterial strains used and culture conditions applied in the growth antagonism experiments.
S. thermophilus NCC1561, S. thermophilus NCC 1536 and L. lactis NCC2211 (killer strains) were tested for growth antagonism against A. naeslundii OMZ745 and A. viscosus OMZ105 (target strains).
Procedure
- Grow the killer strains overnight on agar plates in anaerobiosis and the target strains in BHI until middle stationary phase
- Dilute 20 μl of the target strains suspension in 3 ml of BHI soft agar (agar 7 g/1) containing glucose and lactose, vortex and pour immediately on a BHI agar plate
- Solidify for 1 h at room temperature, then streak the killer strain from the M17 plate in the form of a cross. Streak in parallel the killer and the target strains alone as a control
- Incubate at 37 °C in anaerobiosis for 24 hours
Growth antagonism is revealed by an inhibition halo around the cross.
Statisticals
Differences between the control and test consortia were determined by Student's t test.
RESULTS AND DISCUSSION
S. thermophilus NCC 1561 and L. lactis NCC2211 could be incorporated and grown in the plaque-like biofilm on the S-HA discs, and their total CFU/disc after 40.5 h are given in the Table 4.
Table 4. Level of incorporation of the two dairy strains in the biofilm (CFU/disc). The values are the mean of three experiments with their standard deviations.
The effect of incorporating the dairy strains in the biofilm on the oral species is indicated in the Tables 5 and 6. When S. thermophilus NCC 1561 was included (Table 5), a general decrease of the total flora, that is represented by the counts on Columbia blood agar plates (CBA), and of 4 of the oral species was noticed.
When L. lactis NCC2211 was introduced in the oral strains consortium (Table 6) the total flora counts notably diminished (CFU on CBA). The decrease was significant in the case of A. naeslundii OMZ745 that significantly diminished (p = 0.021) The decrease was even stronger if the strain was inoculated on the discs before the oral bacteria.
Table 5 Modulation of the oral strains consortium by S. thermophilus NCC 1561
N = 3. *: p-values are calculated in respect to the control (*: p<0.05; **: p<0.01); °: p- values are calculated in respect to the "+NCC1561" treatment (°: ρ<0.05; °°: p<0.01).
Table 6. Modulation of the oral strains consortium by L. lactis NCC2211
N = 3. *: p-values are calculated in respect to the control (*: p<0.05; **: p<0.01); °: p- values are calculated in respect to the "+NCC2211" treatment (°: p<0.05; °°: p<0.01).
Some assays were carried out to verify if the reduction of the oral strains was due to growth antagonism of the dairy strains towards them (Table 7). The strains A. viscosus OMZ105 and S. thermophilus NCC1536 were also included in the test since they are part of the in vivo model (example2)
All the four dairy strains inhibited the growth of the Gram-negative strain A. viscosus OMZ105. This inhibition cannot be attributed to lactic acid production. A. viscosus is able to metabolize lactate only under aerobic conditions (van der Hoeven et al. (1990) Oral Microbiol. Immunol. 5, 223-225) and it is very aciduric. These findings have been confirmed by plating A. viscosus in presence of 1% lactic acid: no inhibition was observed.
Table 7. Oral strains growth inhibition by S. thermophilus NCC 1561, S. thermophilus NCC1536 and £. lactis NCC211.
CONCLUSIONS
S. thermophilus NCC1561 and L. lactis NCC2211 could be incorporated in a biofilm mimicking dental plaque and were able to modulate the oral microflora, significantly reducing the number total of cfu, and more specifically, these strains were able to significantly decrease the colonization extent of A. naeslundii genospecies 2. In addition the strains could inhibit the growth of A. naeslundii genospecies 1 and 2 in co-cultures.
Example 2: in- vivo trials.
An in-vivo study was performed on a rat model. In this study, the association of the selected strains was continued during the whole experimental period on a daily basis, by the way of a chilled dairy product feeding.
The study was carried out in 58 days. In order to perform the experiment during the day, the active period of the animals had to be advanced of 7 hours totally; this was done in three steps on day 16, 17 and 18 as further described in detail. The cariogenic strains were associated on days 21 and 22, while association of the dairy strains started on day 23 and lasted until day 57. The animals were fed the dairy strains as supplement in a yogurt base that was
included in the normal diet, as explained in the section. The rats teeth were swabbed at the end of the study, on day 58.
Animals and diet
10 litters consisting of 4 Osborne-Mendel rats pups each (animal production section of the Institute fur Orale Mikrobiologie und Allgemeine Mikrobiologie, University of Zurich, Zurich, Switzerland) were used in the experiment. All animals were weighed at the beginning and at the end of the experimental period. When 13 days old, the dams and the pups were transferred to screen-bottom stainless-steel cages without bedding and nourished with low- fluoride powdered (0.2 μm) Nafag diet to avoid fissure impaction (Rat Checkers No. 184, NAFAG, Gossau SG, Switzerland), and tap water ad libitum. The active phase during which the rats eat is during the night, i. e. 18:00 - 06:00. In order to allow refilling of the food cups during normal working hours, the circadian biorhythm was stepwise reversed between days 16 and 18 by advancing the active phase of the rats each day on three occasions by adjusting the automatic light controls.
On day 16/17 the beginning of the active period was brought forward from 18:00 h to 15:00 i. .e. it was night from 15:00 - 03:00 and it was day onwards. On day 17/18 the beginning of the active period was brought forward from 15:00 to 12:00 h, i. e. it was night from 12:00 h - 00:00 h and day from 00:00 h onwards.
Finally on day 18/19 the beginning of the active period was brought forward from 12:00 to 10:00 i. e. it was night from 10:00 h to 22:00 h and day from 22:00 h onwards.
Therefore by day 19 the shift of the active phase for the rats from the hours of darkness to normal working hours (10:00 - 22:00 h) was completed.
On day 20 the dams were removed, and the rats started to be fed ad libitum with the modified diet 2000a containing 40% sucrose, 28% substitute for skim milk (soya protein extract SVPRO-PP 1611 39.4%, lactose 49.3%, 0.6%, L- Methionine 0.3%, L-Lysine HC1 0.1%), 24% wheat flour, 5% brewer's yeast, 2% Gevral® Instant Protein (Whitehall-Robins SA, 6301 Zug, Switzerland) and 1% NaCl. During the association period (days 21 and 22) the drinking water was supplemented with 2% glucose and 2% sucrose to support the implantation of the associated bacteria. On day 23 the litters were distributed among the 3
treatments, 1 animal per cage, in a programmed feeder machine and began to receive the test diet as indicated in the table 10. The test diet consisted of 18 yogurt meals containing the test strains alternating with 18 meals of the modified diet 2000a previously described.
Drinking water was supplied ad libitum. Following the swabbing procedure on day 58 the animals were overdosed with Thiopental sodium (100 mg/Kg of body weight) given by intra-peritoneal injection and decapitated when comatose.
Bacterial strains : The strains listed in the Table 8 were used.
Table 8 Bacterial strains that were used in this study
Preparation of the tested LAB strains for the association.
A preliminary study was done to assess the growth parameters, especially the hours required to reach the stationary phase in the specific conditions further described. It was therefore established to grow the S. thermophilus strains for 7 h and the L. lactis one for 6 h. Also a study of the viability after freezing of the dairy strains was performed by plating the same cell suspension before and after freezing. In order to be associated to the animals, the dairy strains were treated according to the following procedure.
Procedure
- Inoculate the strains 1% overnight in their proper medium from a glycerol stock
- Inoculate them 5% from this culture into 10 batches of 4 liters of their proper medium pre-heated at the optimal growth temperature, and grow them until the end of the log phase/beginning stationary phase
- Determine the final CFU/ml by plating on M17-lactose agar from two randomly chosen batches for each of the 4 strains. Incubate the plates overnight in anaerobiosis.
- Centrifuge the cultures from each batch at 6000 rpm for 10 min and re- suspend the pellets in 150 ml of fresh medium; keep overnight at 4°C
- Centrifuge again and re-suspend in the freezing medium (15% glycerol in Belliker or M17).
- Split in aliquots in order to have 2xlOH viable cells/vial, taking into account the viability loss due to freezing, and store at -20°C until needed.
Association of the animals with the bacterial strains
The animals were arranged in 3 treatments (Table 9). Each treatment consisted of 10 pups that were distributed in 1 per cage.
Table 9. Arrangement of the treatments.
Treatment Associated bacteria
1 A. viscosus OMZ105; S. thermophilus NCC1536 2 A. viscosus OMZ105; S. thermophilus NCC 1561 3 A. viscosus OMZ105; L. lactis NCC2211
All the rats were first infected on days 21 and 22 with A. viscosus OMZ105.
The tested LAB strains were associated daily (since contained in the yogurt base meal), starting on day 23. 2 frozen vials, each containing 2xlOπ viable cells of the test strain, were mixed in 200 ml of yogurt in order to have at least 109 CFU/ml. S. thermophilus NCC1536, a non S-HA adhering strain, was used as a negative control.
The yogurt and diet 2000a meals, of 1 ml and 400 mg respectively, were offered alternatively 18 times per day at 20-min intervals (Table 10). Therefore, each animal received in total 18 ml of yogurt and 7.2 g of powdered diet.
The meals were dispensed in the food cups of a programmed feeder machine that automatically offered to the animals the right meal at the exact time.
Table 10. Eating times.
Bacteriological evaluation
Five rats per treatment were swabbed on day 58. The swab suspensions were either plated on Petri dishes for CFU (colony forming units) counts or immobilized on glass slides for immunofluorescence for TCN (total cells number) counts.
Procedure for CFU determination
- Swab rats' teeth with a sterile cotton-tipped stick and place it immediately in 5 ml of sterile NaCl 0.9%
- Vortex for 1 min and sonicate for 5 s at 50 W
- Spirally plate the properly diluted suspensions on CBA, MS and HJL agar - Incubate CBA and MS plates at 37 °C and HJL plates at 45 °C.
Procedure for TCN determination
- Put 10 μl of the undiluted swab suspension prepared for CFU determination per well on a 24 wells glass slide (Dynatech Produkte AG, Embrac Embraport, Switzerland), and air dry
- Fix by soaking in methanol for 2 min and air dry - Incubate with 10 μl of the proper antibody or serum diluted in ELISA buffer (section 4.2.2.5) and incubate at 37 °C for 30 min
- Aspirate each drop from the side of the well and wash by soaking the slide first in ELISA buffer and then in distilled water. Air dry
- Apply 10 μl of goat-anti-rabbit IgG (H + L) - FITC (Sigma) diluted 1:400 and incubate at 37 °C for 30 min
- Wash as before and air dry
- Apply 49 μl of mounting fluid (section 4.2.2.5), cover with a glass slip and count the fluorescent cells with a fluorescence microscope
Statistics
Data were treated with two-way ANOVA ((Snedecor and Cochran, 1980)).
RESULTS from the continuous association of the dairy strains by the way of a chilled dairy product feeding.
Bacteriological evaluation (Table 11)
- Colonization of the strain. 1.7 (+/- 1.1) xlO7 CFU were counted for the plaque forming A. viscosus OMZ105, when the dairy product was supplemented with the non-adherent S. thermophilus control (NCC 1536). The dairy strains could not be counted by microbiological methods. By immunofluorescence, however, a qualitative evaluation was tempted. The three adherent dairy strains could be recognized in the plaque samples from treatments 2 and 3. Since they were co-aggregated with other oral bacteria and mouth debris, thus generating big clusters, a precise quantification was impossible.
- Variations in the total flora (TF). The three treatments containing the adherent tested strains S. thermophilus NCC 1561 and L. lactis NCC2211 displayed significant reduced numbers of colony forming units on CBA compared with the control group containing the non-adherent strain S.
thermophilus NCC 1536 (Table 11). Treatment 2 reduced the CFU counts with a significant factor of PF<0.01 and treatment 3 even more significantly (PF<0.001).
- Modulation of A. viscosus OMZ105 tooth colonization by the tested strains.
In the case of the plaque forming bacterium A. viscosus OMZ105, an apparently less pronounced but more significant decrease in the number of colony forming units was observed for the three treatments containing the tested adherent strains with respect to treatment 1 (PF<0.01) (Table 11). By contrast the percentages of A. viscosus on the total CFU counts were not significantly different. Approximately 50% of the total CFU for all four treatments were identified as A. viscosus colonies.
Table 11. Mean values per rat of colony forming units for the total flora (TF) and A. viscosus OMZ105 and their respective percentages (N = 5).
Treatments 2-3 were compared with treatment 1. SEM = standard error of the mean; n.s. = not significant. CBA = Columbia Blood Agar; MS = Mitis-salivarius agar. OMZ105: A. naeslundii genospecies 2.
In this in vivo assay, the strains that were supplied daily, displayed clear inhibitory effect on the total microflora, whose CFU significantly diminished. This diminution can be explained by the growth antagonism of the dairy strains versus oral species. For instance in vitro, all of them, including the non S-HA
adhering S. thermophilus NCC 1536, can inhibit the growth of A. viscosus OMZ105. However, in vivo such an effect can only be displayed by the S-HA adhering strains, since it was detected in the treatments 2-4 compared to the first.
In particular, since the animals had been infected with A. viscosus
OMZ105, the quantification of this plaque-forming organism was possible at the end of the experimental period, and the decrease of its CFU could be closely monitored.
The percentages of A. viscosus OMZ105 on the total CFU did not decrease in parallel, therefore one can deduce that the growth antagonism effect was also displayed versus other species, i.e. Veillonellae, and consequently it is a global effect which is observed.
Thus the strains CNCM 1-1985 and CNCM- 1986 are able to modulate the oral microbial ecology, significatively decreasing the colonization extent of A. naeslundii genospecies 2, with which the rats had been infected.
Example 3: Production and initial analysis of surfactant substances from S. thermophilus NCC1561 and S. thermophilus NCC1536.
S. thermophilus NCC1561 and S. thermophilus NCC1536 were grown overnight in 1 1 of Belliker at 42 °C. For biosurfactant production, the procedure described in Busscher et al. (1997) Appl. Environ. Microbiol. 63, 3810-3817, (Busscher et al., 1997) was used.
Preparation of the surfactant substances
Procedure
- Wash cells three times in PBS
- Resuspend in 200 ml of distilled water or PBS
- Produce the biosurfactant by gently stirring the suspension for 2 or 4 h at room temperature - Separate bacteria by centrifugation at 10000 rpm for 10 min
- Centrifuge supernatant twice at 10000 rpm for 10 min
- Freeze-dry and weigh both the pellet and the surfactant substances solutions.
The crude biosurfactant suspension was first analyzed by SDS-PAGE and then submitted to surface tension measurements.
Procedure for SDS-PAGE
SDS-PAGE was carried out with a precast 12.5% ExcelGel (Amersham Pharmacia Biotech). Silver staining was performed with the Plusone Silver Staining Kit (Amersham Pharmacia Biotech).
Procedure for surface tension measurement
The surface tension of the biosurfactant suspensions was measured with a TVT1 Drop Volume Tensiometer (Lauda, Lauda-Kδnigshofen, Germany), which is based on the drop volume principle. Briefly, the method cqnsists in the exact determination of the volume of a suspension drop that detaches from a capillary. This volume (critical volume) is proportional to the surface tension (σ), whose value is calculated with the relation: σ = V g Δp F/ 2πrcap where: - σ is the interfacial tension
- V is the drop volume
- G is the acceleration constant
- Δp is the difference of the densities of both adjacent phases
- F is the correction factor - rcap is the radius of the capillary
The measurements were done in duplicate at 37 °C against air. Each measurement consisted of 10 cycles. A solution of 6 mg/ml of crude product released, made the water surface tension decrease from 70 to 51 mN/m (Table 13). SDS-PAGE profile of the bacteria released products, showed that there were many different substances of proteinaceous nature in the solution.
Table 13. Surface tension values of the biosurfactant suspensions compared to water and PBS. The values are the mean of two experiments, each one consisting of ten measurements.
RESULT
S. thermophilus NCC1561 and S. thermophilus NCC1536 cells are able to release substances with a surfactant activity. It is therefore possible that the biosurfactant produced by S. thermophilus NCC 1561 makes the bacterium itself and the other oral strains established close to it detach from the tooth surface. By contrast, this action would not be displayed by S. thermophilus NCC 1536, since this strain does not adhere to the teeth.
Example 4: TOOTHPASTE
Toothpaste is prepared by adding 105 cfu/ml of at least one of the lactic bacteria strain CNCM 1-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987 in a lyophilised form, to the following mixture containing: 1.65% Cetyl pyridinium chloride, 33.0% Sorbitol (70% soln), 25.0% Glycerin, 2.0% Sodium carboxymethyl cellulose, 0.25% Sodium fluoride, 26.3% Silica (RP 93), 8.1% Thickening Silica (Sident 22), 0.5% Sodium saccharine, 3.2% Poloxamer (Pluronic F108).
This toothpaste is intended for the prophylaxis or the treatment of root caries, dental plaque and other infections induced by A.naeslundii species.
Example 5: YOGHURT
5 1 MRS culture medium are sterilised for 15 min at 121°C and then inoculated with 5% by volume of an active culture of at least one of the
S. thermophilus strain CNCM 1-1984, CNCM 1-1985 containing approximately 10 cfu/ml. After incubation for 8 h at 41°C, a starter containing 4.5.10 cfu/ml is obtained.
5 1 reconstituted skimmed milk having a dry matter content of 10%, to which 0.1% yeast extract has been added, are sterilised for 15 min at 121°C and inoculated with 2% of an active culture of commercial thickening Streptococcus thermophilus containing approximately 109 cells/ml. After incubation for 4 h at
41°C, a starter containing 4.5.10 cells/ml is obtained.
One batch of whole milk containing 3.7% fats strengthened with 2.5% skimmed milk powder and then pasteurised for 30 min at 90°C is then inoculated with 2% by volume of the starter of at least one of the strains CNCM 1-1984, CNCM 1-1985 and 3% by volume of the starter of thickening Streptococcus thermophilus. The inoculated milk is stirred, poured into pots and incubated for 4 h at 41°C.
The yoghurt obtained has a good firm and smooth texture and is intended for the health of the mouth.
Example 6: CHEWING GUM
A chewing gum for preventing or treating root caries, dental plaque or other A.naeslundii-τela.ted deseases can be prepared adding an active culture of at least one of the S. thermophilus strain CNCM 1-1984, CNCM 1-1985 so that it contains approximately 104 to 109 cfu/g, to the following typical ingredients: 67.5 % Xylitol, 20 % Gum base, 5 % Calcium carbonate, 3 % Glycerin, 2 % Pluronic F127, 1 % Cellulose gum, 0.5 % Balast compounds and 1 % Flavor.
Example 7: PET FOOD COMPOSITION
A pet food for mouth health is obtained by preparing a feed mixture made up of corn, corn gluten chicken and fish meal, salts, vitamins and minerals. The feed mixture is fed into a preconditioner and moistened. The moistened feed leaving the preconditioner is then fed into an extruder-cooker and gelatinised. The gelatinised matrix leaving the extruder is forced through a die and extruded. The extrudate is cut into pieces suitable for feeding to dogs, dried at about 110°C for about 20 minutes and cooled to form pellets which have a water activity of about 0.6.
The pellets are sprayed with 3 coating mixtures. Each coating mixture contains active culture of at least one of the S. thermophilus strains CNCM I- 1984, CNCM 1-1985 but one coating mixture uses hydrogenated soy fat as a coating substrate, one coating mixture uses water as a coating substrate and one coating mixture uses protein digest as a coating substrate. The pellets contain approximately 104 to 109 cfu/g of said strains.
Claims
Claims
1. The use of lactic bacteria strain that is exogenous to the oral microflora, which has been selected for its ability to adhere to the pellicle of the teeth and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.
2. The use according to claim 1, wherein the lactic bacteria strain is from dairy origin.
3. The use according to claims 1 or 2, wherein the lactic bacteria strain is selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis.
4. The use according to one of claims 1 to 3, wherein the lactic bacteria strain is selected from the group consisting of the strains CNCM 1-1984, CNCM I- 1985, CNCM 1-1986, CNCM 1-1987.
5. The use according to one of claims 1 to 4, wherein the composition is an edible composition comprising an effective quantity of lactic bacteria for reducing dental plaque and/or for treating or preventing root caries and other diseases related to Actinomyces naeslundii in mammals.
6. The use according one of claims 1 to 5, wherein the composition contains at least 104-109 cfu /g of the lactic bacteria strain.
7. The use according to one of claims 1 to 6, wherein the lactic bacteria strain is combined with a bacteriocin.
8. A composition for maintaining the health of the mouth by reducing the colonization of Actinomyces naeslundii in mammals, said composition conta ng at least one lactic bacteria strain that is exogenous to the oral microflora, which has been selected for its ability to adhere the pellicle of the teeth and to produce a growth inhibition factor.
9. A composition for maintaining the health of the mouth by reducing the colonization of Actinomyces naeslundii in mammals, said composition comprises :
- a lactic bacteria strain which has been selected for its ability to adhere to the pellicle of the teeth and to produce a growth inhibition factor, and
- a bacteriocin.
10. A composition according to claims 8 or 9, comprising at least one lactic bacteria strain selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis.
l l.A composition according to one of claims 8 to 10, comprising at least one lactic bacteria strain selected from the group consisting of the strains CNCM 1-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987.
12. A composition according to one of claims 8 to 11, comprising at least 104-109 cfu /g of the lactic bacteria strain.
13. A method for the prevention or the treatment of Actinomyces naeslundii- related diseases in mammals, comprising the step of feeding a mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooh surface and to produce a growth inhibition factor.
14. A method according to claim 13, for reducing dental plaque and treating or preventing root caries in mammals.
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-DRGANISMES
AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
DDEESTINATAIRE I RECEPISSE EN CAS DE DEPOT INITIAL, delivre en vertu dβ la regie 7.1 i
SOCIETE DES PRODUITS NESTLE S.A.AUTORITE DE DEPOT INTERNATIONALE
Patents Department identifiee au bas de cette page
Avenue Nestlέ 55 CH-1800 VEVEY
I NOM ET ADRESSE I
DU DEPOSANT
IDENTIFICATION DU MICRO-ORGANISME
Re f erence d ' identif icatiσn dormee par le Numerα d'ordre attribue' par DEPOSANT : l'AUTORITE DE DEPOT INTERNATIONALE
NCC 1529 1 - 1984
II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE
Le micro-organisme identifie sous chiffre I etait accompagna d'une description scientifique
d*une designation taxonomique proposes
(Cocher ce qui convient)
III. RECEPTION ET ACCEPTATION
La presente autαrite de depot Internationale accepte le micro-organisme identifie sous chiffre I, qu'elle a recu le 03 MARS 1998 (date du depot initial)1
IV. RECEPTION D'UNE REQUETE EN CONVERSION
La presente autorite de depot internationale a recu le micro-organisme identifie sous chiffre I le (date du depot initial) et a re u une requete e conversion du depot initial en depot conforme au Traitέ de Budapest le (date de reception de la requete en. conversion)
V. AUTORITE DE DEPOT INTERNATIONALE
Norn Signature(s) de la (des) personnels)
CNCM competente ( s ) pour representer l'autorite
Collection Nationale de depot Internationale on de l'(des) de Cultures de Mioroorgamsmes employe (s) autorise(s) : me Y. CERISIER
OitecteUf Adm rastralif de la GNCM
Adxe s se 1NSTITUT PASTEUR
28, RUB du Docteur Roux F-75724 PARIS CEDEX 15 Date Paris,
1 En cas ά' application de la regie δ.ή.d), cette date est la data a laquelle le statut d'autoπte de depδt internationale a eta acquis.
Fαrmule BP / h (page unique)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-ORGANISMES
AUX PINS DE LA PROCEDURE EN ATIERE DE BREVETf
EORMULE INTERNATIONALE DESTlNATAIRE i | RECEPISSE EN CAS DE DEPOT INITIAL, deli re en vertu de la regie 7.1 par
SOCIETE DES PRODUITS NESTLE S.A\AUTORITE DE DEPOT INTERNATIONALE
Patents Department identifiee au bas de cette page
Avenue Nestle" 55 CH-1S00 VEVEY
I NOM ET ADRESSE I DU DEPOSANT
I. IDENTIFICATION DU MICRO-ORGANISME
Reference ' identification dαnnee par le Nuπierα d*αrdre attrifcue par DEPOSANT : 1» AUTORITE DE DEPOT INTERNATIONALE
NCC 1561 1-1985
II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE
Le micro-organisme identifie sous chiffre I etait accompagne d'une description scientifique
d'une designation taxonomique proposee
(Coder ce qui convient)
111. RECEPTION ET ACCEPTATION
La presente autorite de depot internationale accepte le micro-organisme identifie sous chiffre I, qu'elle a recu le 03 MARS 1993 (date du depot initial)
IV. RECEPTION D'UNE REQUETE EN CONVERSION
La presente autorite de depot internationale a recu le micro-organisme identifie sous chiffre I le (date du depot initial) et a recu une requete en conversion du depot initial en depot conforme au Traite de Budapest le (date de reception de la requete en conversion)
V. AUTORITE DE DEPOT INTERNATIONALE
Horn Signature(s) de la (des) personne(s)
CNCM competente(s) pour representer L'autorite
Collection Nationale de depot internationale ou de l' fdes) de Cultures de icroorganismes employe (s) autorise(s) : Mme Y. CERISIER
Dlrecleur Admimslralif de la CNCM
Adress e INSTITUT PASTEUR
28, Rue du Docteur Roux F-75724 PARIS CEDEX 15 Date
1 En eas d ' application de la regie 6.4.d) , cette date est la date laquelle le statut d'autorite de depot internationale a ate acquiε .
Formule BP/4 (page unique)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-ORGANISMES
AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
ri)ESTINATAIRE : | RECEPISSE EN CAS DE DEPOT INITIAL, delivre en vertu de la regie 7.1 par
SOCIETE DES PRODUITS NESTLE
DE DEPOT INTERNATIONALE
Paents Depart nt identifiee au bas de cette page
Avenue Nestlέ 55 CH-1800 VEVEY
I NOM ET ADRESSE I DU DEPOSANT
1. IDENTIFICATION DU MICRO-ORGANISME
Reference d'identi ication donnee par le Nuπiero d'ordre attribue par DEPOSANT : 1' AUTORITE DE DEPOT INTERNATIONALE
NCC 2211 1-1986
II- DESCRIPTION SCIENTIF1QUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE
Le micro-organisme identifie sous chi fre I e ait accompagne' d 'une description sclent fique
d'une designation taxono ique proposee
(Cocher ce qui convient)
III. RECEPTION ET ACCEPTATION
La presente autorite de depδt Internationale accepte le raicro-organisme identifie sous chiffre I, qu'elle a recu le 03 MARS 1998 (date du depot initial)
IV. RECEPTION D > UNE REQUETE EN CONVERSION
La presente autorite de depot Internationale a recu le micro-organisme identifie sous chiffre I le (date du depot initial) et a recu une requete en conversion du depot initial en depot conforme au Traite de Budapest le (date de reception de la rεquSte en conversion)
AUTORITE DE DEPOT INTERNATIONALE
CNCM Signature(s) de la (des) personne(s) competente(s) pour repr senter l'autorite
Collection Nationale de depθt internationale αu de l'(des) de Cultures de Microorganismes employe (s) autorise(s) : Mme Y. CERISIER
Directeur Administratif de la CNCM
Adre sse INSTITUT PASTEUR
28, Rue du Docteur Roux F-75724 PARIS CEDEX 15 Date
1 En cas d ' application de la regie 6.4.d), cette date est la date a laquelle le statut d'autorite de depot internationale a ete acquis .
Formule BP/4 (page unique)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE INTERNATIONALE DU DEPOT DES MICRO-ORGAN1SMES AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
DDEE:STINATAIRE I RECEPISSE EN CAS DE DEPOT INITIAL, delivre en vertu de la regie 7.1 par
SOCIETE DES PRODUITS NESTLE S.A\AUTORITE DE DEPOT INTERNATIONALE
Patents Depart ent identifiee au bas de cette page
Avenue Nestle 55 CH-1800 VEVEY
J N ET ADRESSE I
' — D mEfPnnOcSA Λ MNTTi '
IDENTIFICATION DU MICRO-ORGANISME
Reference d' identi ication donnee par le Numerα d'ordre attribue par DEPOSANT : 1»AUTORITE DE DEPOT INTERNATIONALE
NCC 2225 1 - 1987
II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE
Le micro-organisme identifie sous chiffre 1 etait accompagne d'une description scientifique
d'une designation taxonomique prσposέe
(Cocher ce qui convient)
III. RECEPTION ET ACCEPTATION
La presente autorite de depot Internationale accepte le micro-organisme identifie sous chiffre I, qu'elle a recu le 03 MARS 1998 (date du depot initial) 1
IV. RECEPTION D'UNE REQUETE EN CONVERSION
La presente autorite de depot Internationale a recu le micro-organisme identifie sous chiffre I le (date du depot initial) et a recu une requete en conversion du depot initiaL en depδt conforme au Traite de Budapest le (date da reception de la requete en conversion)
AUTORITE DE DEPOT INTERNATIONALE
S ignature ( s ) de la ( des ) personne l s )
CNCM compe tenta ( s ) pour representer l ' au torite
Collection Nationale de depot internationale ou de l ' ( des ) de Cultures da Microorganismes employe ( s ) autorise ( s ) : Mme Y. CERISIER
Directeur Adminislratif dβ la CNCM
Adress e INSTITUT PASTEUR
28, Rue du Docteur Roux
F-75724 PARIS CEDEX 15 Date : Paris, le 02 avril 1998
1 En cas d ' application de la regie 6.4.d), cette date est la date a laquelle le statut d'autorite de depot internationale a ete acquis.
Formule BP/4 (page uniqtie)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-ORGANISMES
AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
DECLARATION SUR LA VIABILITE,
DESTINATAIRE ~l delivree en vertu de la regie 10.2 par 1 'AUTORITE DE DEPOT INTERNATIONALE
Monsieur F. GROS identifiee a la page suivante
Patents Department
SOCIETE DES PRODUITS NESTLE S.A.
Avenue Nestlέ, 55
CH-1800 VEVEY
NOM ET ADRESSE DE LA PARTIE I A LAQUELLE LA DECLARATION SUR LA I I VIABILITE EST DELIVREE I
DEPOSANT II. IDENTIFICATION DU MICRO-ORGANISME
Nirmero d ' ordre attribue par
Nom ; SOCIETE DES PRODUITS NESTLE S.A. 1 'AUTORITE DE DEPOT INTERNATIONALE
1 - 1984
A ess e : Patents Department Avenue Nestlέ 55 Date du depot ou du transfert : CH-1800 VEVEY 03 MARS 1998
III. DECLARATION SUR LA VIABILITE
La viabilite du micro-organisme identifie sous chiffre II a ete contrόlee le 03 MARS 1998 2- A cette date, le micro-organisme
■ etait viable
n'etait plus viable
1 Indiquer la date du depot initial ou, si un nouveau depot ou un transfert ont ete effectues, la plus recente des dates pertinentes (date du nouveau depot ou date du transfert) ,
2 Dans les cas vises a la regie 10.2. )ii) et iii), mentionner le contrόle de viabilite le plus recent.
3 Cocher la case qui convient .
Ho mule BP/9 (premiere page)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-ORGANISMES
AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
DECLARATION SUR LA VIABILITE,
( DDEESTINATA1RE ~l delivree an vertu dβ la regie 10.2 par 1 'AUTORITE DE DEPOT INTERNATIONALE
Monsieur F. GROS identifiee a la page suivante
Patents Department
SOCIETE DES PRODUITS NESTLE S.A.
Avenue Nestle, 55
CH-1800 VEVEY
NOM ET ADRESSE DE LA PARTIE i A LAQUELLE LA DECLARATION SUR LA
VIABILITE EST DELIVREE
1 Indtquer la date du depot initial ou , si un nouveau depot ou un transfert ont ete effectues, la plus recente des dates pertinentes (date du nouveau depot ou date du trans ert),
2 Dans les cas vises a la regie 10.2.a)li) et iii), mentionner le contrδle dβ viabilite le plus recent.
3 Cocher la case qui convient.
Formula BP/9 (premiere page)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-ORGANISMES
AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
~ DECLARATION SUR LA VIABILITE,
DDEESTINATAIRE l delivree en vertu de la regie 10.2 par 1 'AUTORITE DE DEPOT INTERNATIONALE
Monsieur F. GROS identifiee a la page suivante
Patents Department
SOCIETE DES PRODUITS NESTLE S.A.
Avenue Nestlέ, 55
CH-1800 VEVEY
NOM ET ADRESSE DE LA PARTIE A LAQUELLE LA DECLARATION SUR LA I VIABILITE EST DELIVREE I
I . DEPOSANT II . IDENTIFICATION DU MICRO-ORGANISME
Numero d 'ordre attribue par
Nom : SOCIETE DES PRODUITS NESTLE S.A. 1 'AUTORITE DE DEPOT INTERNATIONALE :
1 - 1986
Ad esεe : Patents Department Date du depot ou du transfert : Avenue Nestlέ 55 CH-1800 VEVEY 03 MARS 1998
III . DECLARATION SUR LA VIABILITE
La viabilite du micro-organisme identif ie sous chiff re II a ete contrβlee i' le 03 MARS 1998 2 - A cette d ate , le micro-organisme
jB jj etait viable
n ' etait plus viable
1 Indiquer la date du depot initial ou, si un nouveau depot ou un transfert ont ete effectues, la plus recente des dates pertinentes (date du nouveau depot ou date du transfert).
2 Dans les cas vises a la regie 10.2.a)ii) et iii), mentionner le contrόle de viabilite le plus recent.
J Cocher la case qui convient.
Ormule BP/9 (premiere page)
TRAITE DE BUDAPEST SUR LA RECONNAISSANCE
INTERNATIONALE DU DEPOT DES MICRO-ORGANISMES
AUX FINS DE LA PROCEDURE EN MATIERE DE BREVETS
FORMULE INTERNATIONALE
DECLARATION SUR LA VIABILITE,
DDEESTINATAIRE ~l delivree en vertu de la regie 10.2 par 1'AUTORITE DE DEPOT INTERNATIONALE
Monsieur F. GROS identifiee la page suivante
Patents Department
SOCIETE DES PRODUITS NESTLE S.A.
Avenue Nestlέ, 55
CH-1800 VEVEY
NOM ET ADRESSE DE LA PARTIE
LA LAQUELLE LA DECLARATION SUR LA VIABILITE EST DELIVREE
1 Indiquer la date du depot initial ou, si un nouveau depot ou un transfert ont ete effectues, la plus recente des dates pertinentes (date du nouveau depot ou date du trans ert).
2 Dans les cas vises a la regie 10. .a)ii) et iii), mentionner le contrδle de viabilite le plus recent.
J Cocher la case qui convient.
formule BP/9 (premiere page)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15312701A IL153127A0 (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| AU7244901A AU7244901A (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| HU0301271A HUP0301271A2 (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| JP2001587727A JP2003534362A (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic acid strains for Actinomyces naeslundii related diseases |
| NZ522911A NZ522911A (en) | 2000-06-02 | 2001-05-30 | A composition for reducing dental plaque and/or preventing root caries comprising an exogenous lactic acid bacterial strain |
| AU2001272449A AU2001272449B2 (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| BR0111371-2A BR0111371A (en) | 2000-06-02 | 2001-05-30 | Use of a genus of exogenous lactic acid bacteria against naeslundii-related actinomyces diseases |
| MXPA01001038 MXPA01001038A (en) | 2000-06-02 | 2001-05-30 | Incorporation of exogenous lactic bacteria in the microflora or |
| PL360850A PL202576B1 (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii |
| EP01951549A EP1296636B1 (en) | 2000-06-02 | 2001-05-30 | USE OF EXOGENOUS LACTIC BACTERIA STRAIN AGAINST i ACTINOMYCES NAESLUNDII /i RELATED DISEASES |
| DE60124255T DE60124255T2 (en) | 2000-06-02 | 2001-05-30 | USE OF EXOGENOUS MILKY ACID BACTERIA FOR THE TREATMENT OF DISEASES CAUSED BY ACTINOMYCES NAESLUNDII |
| MXPA02011973 MX243373B (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii. |
| CA002410591A CA2410591A1 (en) | 2000-06-02 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| US10/305,024 US20030170184A1 (en) | 2000-06-02 | 2002-11-27 | Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains |
| US10/995,891 US7491386B2 (en) | 1998-08-12 | 2004-11-23 | Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00201948.7 | 2000-06-02 | ||
| EP00201948A EP1159951A1 (en) | 2000-06-02 | 2000-06-02 | Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/779,596 Continuation US6942849B2 (en) | 1998-08-12 | 2001-02-09 | Incorporation of exogenous lactic bacteria into the oral microflora |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/305,024 Continuation US20030170184A1 (en) | 1998-08-12 | 2002-11-27 | Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001091711A1 true WO2001091711A1 (en) | 2001-12-06 |
Family
ID=8171588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2001/006268 WO2001091711A1 (en) | 1998-08-12 | 2001-05-30 | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20030170184A1 (en) |
| EP (2) | EP1159951A1 (en) |
| JP (1) | JP2003534362A (en) |
| KR (1) | KR20030031490A (en) |
| CN (1) | CN1279890C (en) |
| AR (1) | AR028672A1 (en) |
| AT (1) | ATE343932T1 (en) |
| AU (2) | AU7244901A (en) |
| BR (1) | BR0111371A (en) |
| CA (1) | CA2410591A1 (en) |
| DE (1) | DE60124255T2 (en) |
| ES (1) | ES2275697T3 (en) |
| HU (1) | HUP0301271A2 (en) |
| IL (1) | IL153127A0 (en) |
| IN (1) | IN2002CH01972A (en) |
| MX (2) | MXPA01001038A (en) |
| MY (1) | MY142363A (en) |
| NZ (1) | NZ522911A (en) |
| PE (1) | PE20011328A1 (en) |
| PH (1) | PH12001001365B1 (en) |
| PL (1) | PL202576B1 (en) |
| PT (1) | PT1296636E (en) |
| UY (1) | UY26748A1 (en) |
| WO (1) | WO2001091711A1 (en) |
| ZA (1) | ZA200210308B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9504739B2 (en) | 2011-03-01 | 2016-11-29 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US11464717B2 (en) | 2017-02-10 | 2022-10-11 | Evonik Operations Gmbh | Oral care composition containing at least one biosurfactant and fluoride |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1287745A1 (en) | 2001-08-24 | 2003-03-05 | The Procter & Gamble Company | Chewable compositions with probiotic agents |
| US8038990B2 (en) * | 2005-06-01 | 2011-10-18 | The Ohio State University | Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces |
| WO2010077795A2 (en) * | 2008-12-16 | 2010-07-08 | Nestec S.A. | Compositions and methods for improved oral health |
| CN115177607A (en) | 2013-09-24 | 2022-10-14 | 密歇根大学董事会 | Compositions and methods for destabilizing, altering and dispersing biofilms |
| CN104546941B (en) * | 2014-09-30 | 2019-01-08 | 深圳华大基因科技有限公司 | Actinomyces naeslundii is treating or preventing the application in rheumatoid arthritis or its related disease |
| EP3302090A1 (en) | 2015-06-08 | 2018-04-11 | Chr. Hansen A/S | Glycerin-based gummy candy and foam candy products with probiotic bacteria |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135739A (en) * | 1983-02-15 | 1992-08-04 | Kitasato Kenkyusho | Non-cariogenic composition and drink |
| WO2000009080A1 (en) * | 1998-08-12 | 2000-02-24 | Societe Des Produits Nestle S.A. | Incorporation of exogenous lactic bacteria into the oral microflora |
| US6036952A (en) * | 1997-08-07 | 2000-03-14 | Oh; Jong Suk | Lactic acid bacteria inhibiting the formation of dental plaque in the mouth |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59220191A (en) | 1983-04-07 | 1984-12-11 | Kitasato Inst:The | Noncariogenic composition and drink |
| US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| CH671879A5 (en) | 1987-02-26 | 1989-10-13 | Nestle Sa | |
| JPH0421633A (en) | 1990-05-17 | 1992-01-24 | Saikon Medics:Kk | Maintenance and control of useful microorganismic flora in lower cavity of living body and maintenance and control composition |
| FR2672494A1 (en) | 1991-02-13 | 1992-08-14 | Madinier Isabelle | PROPHYLACTIC FERMENTS PROMOTING PREVENTION OF DENTAL CARIES. |
| DE4117782C2 (en) | 1991-05-28 | 1997-07-17 | Diagnostikforschung Inst | Nanocrystalline magnetic iron oxide particles, processes for their production and diagnostic and / or therapeutic agents |
| JPH054927A (en) | 1991-06-28 | 1993-01-14 | Aizo Matsushiro | Lactic acid-containing composition and production thereof |
| DE69219768T2 (en) | 1992-07-06 | 1997-08-28 | Societe Des Produits Nestle S.A., Vevey | Milk bacteria |
| GB9224598D0 (en) | 1992-11-24 | 1993-01-13 | Smithkline Beecham Plc | Novel compositions |
| CH684773A5 (en) | 1992-12-28 | 1994-12-30 | Nestle Sa | anti-cariogenic food composition. |
| CO4560537A1 (en) | 1992-12-28 | 1998-02-10 | Nestle Sa | DAIRY COMPOSITION AND PREPARATION PROCEDURE |
| US5368845A (en) | 1993-01-07 | 1994-11-29 | Colgate Palmolive Company | Oral composition |
| US5358858A (en) | 1994-03-17 | 1994-10-25 | National Science Council | Process for preparing phycoerythrin from bangia atropurpurea and porphyra angusta |
| ES2141213T3 (en) | 1994-08-19 | 2000-03-16 | Nestle Sa | BRANCHED POLYSACCHARIDE, MICROORGANISM THAT PRODUCES IT AND COMPOSITIONS THAT CONTAIN IT. |
| EP0776163A4 (en) * | 1994-09-09 | 1999-11-24 | Univ Maryland | Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases |
| JP3101173B2 (en) | 1995-03-22 | 2000-10-23 | 雪印乳業株式会社 | Manufacturing method of frozen yogurt |
| ATE206877T1 (en) | 1995-06-16 | 2001-11-15 | Nestle Sa | FLUORINATED CASEIN MICELLARS |
| ATE234924T1 (en) | 1995-08-07 | 2003-04-15 | Nestle Sa | BACTERIOCIN |
| JP3356599B2 (en) | 1995-09-22 | 2002-12-16 | 雪印乳業株式会社 | Production method of low acidity type frozen yogurt |
| DE10034647C1 (en) * | 2000-07-14 | 2002-04-04 | 3M Espe Ag | Procedure for performing saliva analysis |
-
2000
- 2000-06-02 EP EP00201948A patent/EP1159951A1/en not_active Withdrawn
-
2001
- 2001-05-23 MY MYPI20012436A patent/MY142363A/en unknown
- 2001-05-30 AU AU7244901A patent/AU7244901A/en active Pending
- 2001-05-30 IL IL15312701A patent/IL153127A0/en not_active IP Right Cessation
- 2001-05-30 EP EP01951549A patent/EP1296636B1/en not_active Expired - Lifetime
- 2001-05-30 AT AT01951549T patent/ATE343932T1/en not_active IP Right Cessation
- 2001-05-30 WO PCT/EP2001/006268 patent/WO2001091711A1/en active IP Right Grant
- 2001-05-30 PL PL360850A patent/PL202576B1/en not_active IP Right Cessation
- 2001-05-30 HU HU0301271A patent/HUP0301271A2/en unknown
- 2001-05-30 BR BR0111371-2A patent/BR0111371A/en not_active IP Right Cessation
- 2001-05-30 NZ NZ522911A patent/NZ522911A/en unknown
- 2001-05-30 PT PT01951549T patent/PT1296636E/en unknown
- 2001-05-30 KR KR1020027016456A patent/KR20030031490A/en active Search and Examination
- 2001-05-30 AU AU2001272449A patent/AU2001272449B2/en not_active Ceased
- 2001-05-30 CN CNB018135927A patent/CN1279890C/en not_active Expired - Fee Related
- 2001-05-30 JP JP2001587727A patent/JP2003534362A/en not_active Withdrawn
- 2001-05-30 CA CA002410591A patent/CA2410591A1/en not_active Abandoned
- 2001-05-30 ES ES01951549T patent/ES2275697T3/en not_active Expired - Lifetime
- 2001-05-30 MX MXPA01001038 patent/MXPA01001038A/en not_active Application Discontinuation
- 2001-05-30 DE DE60124255T patent/DE60124255T2/en not_active Expired - Fee Related
- 2001-05-30 MX MXPA02011973 patent/MX243373B/en active IP Right Grant
- 2001-05-31 PH PH12001001365A patent/PH12001001365B1/en unknown
- 2001-05-31 PE PE2001000501A patent/PE20011328A1/en not_active Application Discontinuation
- 2001-06-01 AR ARP010102653A patent/AR028672A1/en unknown
- 2001-06-04 UY UY26748A patent/UY26748A1/en not_active Application Discontinuation
-
2002
- 2002-11-27 US US10/305,024 patent/US20030170184A1/en not_active Abandoned
- 2002-11-29 IN IN1972CH2002 patent/IN2002CH01972A/en unknown
- 2002-12-19 ZA ZA200210308A patent/ZA200210308B/en unknown
-
2004
- 2004-11-23 US US10/995,891 patent/US7491386B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135739A (en) * | 1983-02-15 | 1992-08-04 | Kitasato Kenkyusho | Non-cariogenic composition and drink |
| US6036952A (en) * | 1997-08-07 | 2000-03-14 | Oh; Jong Suk | Lactic acid bacteria inhibiting the formation of dental plaque in the mouth |
| WO2000009080A1 (en) * | 1998-08-12 | 2000-02-24 | Societe Des Produits Nestle S.A. | Incorporation of exogenous lactic bacteria into the oral microflora |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9504739B2 (en) | 2011-03-01 | 2016-11-29 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US9713631B2 (en) | 2011-03-01 | 2017-07-25 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US9717765B2 (en) | 2011-03-01 | 2017-08-01 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US9919012B2 (en) | 2011-03-01 | 2018-03-20 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US10004771B2 (en) | 2011-03-01 | 2018-06-26 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US10086025B2 (en) | 2011-03-01 | 2018-10-02 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US10925908B2 (en) | 2011-03-01 | 2021-02-23 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US11191277B2 (en) | 2011-03-01 | 2021-12-07 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US11825848B2 (en) | 2011-03-01 | 2023-11-28 | Quorum Innovations, Llc | Method of identifying a biologically-active composition from a biofilm |
| US11464717B2 (en) | 2017-02-10 | 2022-10-11 | Evonik Operations Gmbh | Oral care composition containing at least one biosurfactant and fluoride |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU773799B2 (en) | Incorporation of exogenous lactic bacteria into the oral microflora | |
| CN101056972B (en) | Means and methods for preventing and/or treating caries | |
| CN101563447A (en) | Uses and methods for preventing and/or treating caries caused by mutants Streptococci | |
| JP2001512670A (en) | New lactic acid bacteria | |
| AU2001272449B2 (en) | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases | |
| AU2001272449A1 (en) | Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AU BR CA CN CO CR DM HU ID IL IN JP KR MA MX NO NZ PL SG TR US ZA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 153127 Country of ref document: IL Ref document number: 10305024 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2410591 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2001 587727 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001951549 Country of ref document: EP Ref document number: IN/PCT/2002/1972/CHE Country of ref document: IN Ref document number: 2002/02601 Country of ref document: TR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/011973 Country of ref document: MX Ref document number: 522911 Country of ref document: NZ Ref document number: 2001272449 Country of ref document: AU Ref document number: 1020027016456 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002/10308 Country of ref document: ZA Ref document number: 200210308 Country of ref document: ZA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 018135927 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001951549 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020027016456 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 522911 Country of ref document: NZ |
|
| WWG | Wipo information: grant in national office |
Ref document number: 522911 Country of ref document: NZ |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2001272449 Country of ref document: AU |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2001951549 Country of ref document: EP |